发明名称 Gamma secretase inhibitors
摘要 Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.;
申请公布号 US9226927(B2) 申请公布日期 2016.01.05
申请号 US201214342953 申请日期 2012.09.04
申请人 MERCK SHARP & DOHME CORP. 发明人 Wu Wen-Lian;Burnett Duane A.
分类号 C07D493/04;A61K31/4155;A61K31/4245;A61K31/4433;A61K31/497;A61K31/501;A61K45/06 主分类号 C07D493/04
代理机构 代理人 Thies J. Eric;Todaro John C.
主权项 1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of: (1) -pyridinyl, (2) -pyrazolinyl, (3) -1,2,4-oxadiazolyl, (4) -(C1-C2)alkyl-pyridinyl, (5) -(C1-C2)alkyl-pyrazolinyl, and (6) -(C1-C2)alkyl-1,2,4-oxadiazolyl, wherein the pyridinyl, pyrazolinyl, and -1,2,4-oxadiazolyl, is unsubstituted or substited with one L1 group; R1 is independently selected from the group consisting halogen, (C1-C6)alkyl, —CN, —CF3, —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)—OH-substituted (C1-C4)alkyl, halo(C1-C6)alkyl, —(C1-C4)alkoxy-OH, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O)2(C1-C6)alkyl; n is 0, 1, 2, or 3; Ar is selected from the group consisting of phenyl optionally substituted with 1 or 2 L2 groups, and pyridyl optionally substituted with 1 or 2 L2 groups; L1 is independently selected from the group consisting of —OCH3, —NH2, ═O, and (C1-C5)alkyl; and L2 is independently selected from the group consisting of halogen, (C1-C6)alkyl , —CN, —CF3, —O—(C1-C6)alkyl, —O-(halo(C1-C6)alkyl), —C(O)—O—(C1-C6)alkyl, —OH-substituted(C1-C6)alkyl, halo(C1-C6)alkyl, —OH-substituted (C1-C4)alkoxy, —(C1-C4)alkoxy(C1-C4)alkoxy and —S(O)2(C1-C6)alkyl.
地址 Rahway NJ US